BIO 101

Drug Profile

BIO 101

Alternative Names: BIO-101; SARCONEOS

Latest Information Update: 02 Dec 2016

Price : $50

At a glance

  • Originator Biophytis
  • Class Obesity therapies
  • Mechanism of Action Proto-oncogene protein c-mas-1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Muscular atrophy

Most Recent Events

  • 30 Nov 2016 Biophytis completes a phase I trial in Muscular atrophy (In volunteers, In the elderly) in Belgium
  • 22 Nov 2016 Biophytis receives regulatory approvals in France and Belgium for the SARA-OBS trial in Muscular atrophy
  • 22 Sep 2016 Interim adverse events data from a SARA-PK trial in Muscular-atrophy released by Biophytis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top